The biggest multi-decade opportunity for investors right now is the Canadian government’s legislation to legalize recreational marijuana by this time next year—and the first companies to win government approval will the high-risers.
In a sector that’s already seen stocks bust the borders with 1000% spikes, there is one company that currently has 2 of the only 50 licenses to cultivate in Canada, positioning itself to burst out of the gates as new legislation creates a multi-billion-dollar industry over night.
With one of the largest land packages to build cultivation facilities and 2 current licensed facilities located in two provinces in Canada, small-cap Invictus MD (TSX:IMH.V; OTC:IVITF) is set to rise.
It’s already the first licensed medical marijuana company to pay a dividend to shareholders, and with its strains reaching into everything from pain management, cancer, epilepsy, anxiety and – most lucratively of all—recreation, the sky is the limit here.
We’re now just shy of a year away from the start date of legal recreational use, and there are already predictions of a looming supply shortage.
Financial Post reports... there will soon be 3.8 million recreational users... But the market is only currently equipped to handle 150,000 medical marijuana patients.
The industry is scrambling to add growing capacity once the legal barriers are tossed aside.
Deloitte estimates this industry could be worth a whopping $22.6 billion annually. That’s more than the combined sales of beer, wine and spirits.
Right out of the gate, Invictus MD, owner of two of just 50 licenses, has demonstrated that it will lead the way. The company holds $30 million in cash and is already generating dividends—a feat unheard of in the pot industry.
That’s why it’s called ‘Canada’s Cannabis Company’—it’s already cemented market share for medical marijuana use, and now it’s one of the first in and ready to fill the supply gap for a massive recreational push to supply 3.65 million new users.
#1 The Minting of the Next North American Billionaires
When you suddenly legalize a product that’s already got a massive market under the table, you mint billionaires overnight. Just like it did at five o’clock on December 5, 1933—the moment Prohibition ended, and a billion-dollar industry (even then) was reborn.
It’s already happening: The shares of the medical marijuana producers more than tripled last year, just at the prospects.
• AXIM Biotechnologies (NASDAQOTH:AXIM): exploded 1,720 percent
• Corbus Pharmaceuticals (NASDAQ:CRBP) was up 431 percent
• Aphria (NASDAQOTH:APHQF) grew 381 percent
• Aurora Cannabis (NASDAQOTH:ACBFF) was up 299 percent
• Canopy Growth Corp. (NASDAQOTH:TWMJF) up 259 percent
• Medical Marijuana (NASDAQOTH:MJNA) up 254 percent
• GW Pharmaceuticals (NASDAQ:GWPH) was up 64 percent
The smart money is investing too. Tribeca Investment Partners, a boutique fund manager, used bets on marijuana companies to help generate a 145 percent return over the year, according to Fortune magazine and Bloomberg. Nearly US$20 million of its investment gains in 2016 came from marijuana stocks, including Aurora Cannabis and Canopy Growth.
Then, in early April, Canada launched its first marijuana exchange-traded fund (ETF), giving investors diverse exposure to this tantalizing sector. The Horizons Medical Marijuana Life Sciences ETF (TSX:HMMJ) launched on the 4th of April on the Toronto Stock Exchange with 11 Canadian-listed stocks and four U.S.-listed stocks.
On 23 June, Invictus was included in the ETF.
The frenzy surrounding Canada’s marijuana market is palpable, and will be even more frenzied on 1 July 2018.
And Invictus is way ahead of this game: It’s already got a license to produce in this multi-billion-dollar market.
#2 A Pot Pipeline Going in Every Direction
The company’s dream team targets small- and mid-size companies with significant growth potential and directs their strategies towards profitability.
They’ve made some game-changing acquisitions at just the right time; yet, their valuation is far below their peers, making Invictus a real entry point into this lucrative market if you’re looking for outsized gains.
The company owns over 33 percent of AB Laboratories Inc., which received its cultivation license last October. The catalysts here are mounting, with the sales license expected in Q2. This facility has a capacity for 1,000 kilograms, with active expansion plans underway.
In May, Invictus also closed its acquisition of 100 acres with AB Ventures Inc., and is targeting production here of 25,000 kilograms by 2020.
In Alberta, Acreage Pharms received its license to cultivate under ACMPR and has a purpose built 7,000 square foot facility and a 30,000-square-foot expansion plan. Invictus MD currently owns 100 percent of this license.
It’s a brilliant set-up for a small-cap company with CAD$30 million in cash and 78 million basic outstanding shares.
#3 Pot Dividends? The Impossible Because Reality
The logic of Chairman and founder Dan Kriznic is one that shareholders will certainly appreciate: “It made sense to give back [to those] who supported us.”
Not only have shareholders gotten dividends in an industry that generally hasn’t been mature enough to pay out—yet—but there’s a reason this company is a uniquely attractive entry point: Invictus MD’s market cap to funded capacity is about 5 times the industry standard.
Right now, the company has a funded production capacity of about 18,000 kilograms which, compared to its peers, suggests Invictus MD is significantly undervalued.
Its smart acquisitions have made all the difference.
Prior to October, when it entered the license producer market, Invictus MD was busy acquiring all the ‘picks and shovels’ of the cannabis space. Invictus MD has made one smart move after another, and it’s always the ‘pick and shovel’ guys who have real longevity. First, they acquired a fertilizer company that was cash-flow positive, and then they sold one of its lighting divisions for $5 million, having paid only $900,000 for it less than a year before.
They’ve been nurturing their shareholders along with their crops. Invictus MD’s focus on two verticals—cannabis cultivation and cannabis fertilizer and nutrients—gives it a competitive, low-cost advantage on this playing field.
Now they’ve got prime real estate to add to their portfolio, and this is one cash crop that should keep growing.
#4 ‘Top 40 under 40’ in Vancouver
There’s a reason this company is positioned for great things. Kriznic has been rated one of Business in Vancouver’s ‘Top 40 under 40’, and he’s put Invictus on the fast track to the market. He has built over a billion dollars in value for shareholders in his past.
And not only are the strains pre-approved by the health authorities, but they will reach into every corner of this market. It’s a marijuana octopus that has left no stone unturned.
Those strains include high THC strains used to help with pain management and cancer, and high-CBD strains used for epilepsy and anxiety disorders. And when it comes to recreational—the company is gearing up to work on all strains available.
This combined with its tight capitalization structure and access to capital could make this a prime breakout target over the coming weeks and months.
They’re also not new to this game. Invictus MD isn’t just jumping on the green train at the 11th hour; it has been laying the ground work for a very smart expansion strategy.
Kriznic has turned $10-million companies into $150-million annual revenue generators. They’ve got a license to grow in more ways than one, and while they might not be a ‘green giant’ just yet, their undervaluation suggests they could be.
#5 Massive Demand Just Waiting to Be Legalized
The fundamentals are clear—demand is set to further explode once recreational use of cannabis becomes legal.
Where does this leave us with supply? Playing some serious catch-up, which is a producer’s dream. In Canada, legalizing recreational marijuana could result in demand of about 400,000 kilograms of cannabis in its first full year, according to Canaccord Genuity analysts. And that’s just for recreational use. Demand for medical cannabis is also growing at a significant pace, and the total combined demand for the first year could be 575,000 kilograms.
(Click to enlarge)
Arcview Market Research of San-Francisco predicts that legal marijuana sales will reach close to $22 billion by 2021—up from nearly $7 billion last year. That’s an annual growth rate of 26 percent, and it’s in line with Deloitte’s own estimations.
In Canada alone, Canaccord Genuity predicts that the recreational marijuana industry could reach $6 billion in sales by 2021.
If you haven’t considered an entry point into this market yet—the window of opportunity is closing fast. Stocks are already shooting up on anticipation, and by 1 July 2018, high valuations will slam doors shut and only billionaires will come out. By that time, Invictus MD (TSX:IMH.V; OTC:IVITF) should already be walking with the green giants.
Other related companies worth watching:
While Quintiles IMS Holdings, Inc (NYSE:Q) is not a “pot stock,” it is one of the world’s “most admired companies” according to Fortune Magazine. Spanning over 100 countries, Quintiles IMS is definitely ahead of the pack. Quintiles IMS provides research and development solutions that push healthcare forward using data and technology. As the world’s largest contract research organization, this company has secured its place in the medical world.
Intrexon Corp (NYSE:XON) is a leader in the bio-tech field. The company’s biologically-based products and processes are some of the most interesting and important revelations in the medical industry. Designing, building, and regulating gene programs, the company’s technological advancements are ahead of most. As tech continues to fuel medical breakthroughs, Intrexon Corp is definitely worth keeping an eye on.
Insys Therapeutics (NASDAQ:INSY) is generally known as a “marijuana stock” but it would be a bit of a misnomer to lump this company in with pot stocks. Insys’ main product is a sublingual pain medication known as Subsys. However, using the same proprietary sublingual spray technology and their advanced knowledge of synthetic cannabinoids, the company is at the forefront of a new pharmaceutical movement.
Allergan plc Ordinary Shares (NYSE:AGN) is the pharmaceutical company managing some of the most recognized drugs on the planet. This world-renowned generics provider breaks the top 10 in 33 global markets. As the world’s third largest generics company, operating in over 100 countries, Allergan plc is solid pick for those dipping into the world of pharmaceutical stocks.
Not a “pot stock” or a biotech stock, BREW - Craft Brew Alliance Inc (NASDAQ: BREW) is a key figure in the U.S. craft beer marketplace. Representing several breweries from across the country, this company is bringing a voice to one of the hottest trends on the planet. Once simply a niche market, craft beer is catching on fire. Founded in 1981, this alliance is now pumping out 86 million liters of beer per year and it’s only getting started.
By James Burgess
**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**
PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. Oilprice.com, Advanced Media Solutions Ltd, it’s owners, managers, employees, and assigns (collectively “The Company”) has been paid by a third party to disseminate this communication. This compensation is a major conflict with our ability to be unbiased, more specifically:
This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. If we own any shares we will list the information relevant to the stock and number of shares here. We have been compensated by Invictus MD Strategies Corp. to conduct investor relations advertising and marketing for [TSX:IMH.V; OTC:IVITF]. Oilprice.com receives financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the company. The third party, profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which often end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, The Company often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications.
DISCLOSURE. The Company does not make any guarantee or warranty about what is advertised above. The Company is not affiliated with, any specific security. While the Company will not engage in front-running or trading against its own recommendations, The Company and its managers and employees reserve the right to hold possession in certain securities featured in its communications. Such positions will be disclosed AND will not purchase or sell the security for at least two (2) market days after publication.
NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing The Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
FORWARD-LOOKING STATEMENT. As defined in the United States Securities Act of 1933 Section 27(a), as amended in the Securities Exchange Act of 1934 Section 21(e), statements in this communication which are not purely historical are forward-looking statements and include statements regarding beliefs, plans, intent, predictions or other statements of future tense.
PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results
CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR- OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.
All trades, patterns, charts, systems, etc., discussed in this message and the product materials are for illustrative purposes only and not to be construed as specific advisory recommendations. All ideas and material presented are entirely those of the author and do not necessarily reflect those of the publisher. No system or methodology has ever been developed that can guarantee profits or ensure freedom from losses. No representation or implication is being made that using the methodology or system will generate profits or ensure freedom from losses. The testimonials and examples used herein are exceptional results, which do not apply to the average member, and are not intended to represent or guarantee that anyone will achieve the same or similar results.
AFFILIATES. Some or all of the content provided in this communication may be provided by an affiliate of The Company. Content provided by an affiliate may not be reviewed by the editorial staff member. Our affiliates may have their own disclosure policies that may differ from The Company’s policy.
The information contained herein may change without notice.